{"id":"candesartan-cilexetil-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dizziness"},{"rate":"1-3","effect":"Hyperkalemia"},{"rate":"2-5","effect":"Hypokalemia"},{"rate":"3-8","effect":"Headache"},{"rate":"2-5","effect":"Fatigue"},{"rate":"1-2","effect":"Cough"},{"rate":"1-3","effect":"Hyperuricemia"},{"rate":"1-3","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":{"setId":"f3c4f7ed-e667-4528-a675-b032c2a4425d","title":"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLET [MYLAN PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Candesartan cilexetil is a prodrug that is converted to candesartan, an angiotensin II receptor antagonist (ARB) that selectively blocks AT1 receptors, preventing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting sodium and water excretion to reduce blood volume. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Candesartan cilexetil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:48:33.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Reduction of cardiovascular risk in hypertensive patients"}]},"trialDetails":[{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT02774460","phase":"PHASE4","title":"The Precision Hypertension Care Study","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2017-02-20","conditions":"Hypertension","enrollment":280},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04521023","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-09-20","conditions":"Hypertension","enrollment":132},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT02016183","phase":"","title":"Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-04-01","conditions":"Hypertension","enrollment":3222},{"nctId":"NCT02094924","phase":"PHASE1","title":"A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-17","conditions":"Hypertension","enrollment":16},{"nctId":"NCT02521246","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT02521233","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00360178","phase":"PHASE3","title":"Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-07","conditions":"Hypertension","enrollment":198},{"nctId":"NCT00081731","phase":"PHASE3","title":"Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions","status":"COMPLETED","sponsor":"Baim Institute for Clinical Research","startDate":"2004-04","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypertension, Renovascular","enrollment":947},{"nctId":"NCT00232882","phase":"PHASE4","title":"Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients.","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2003-12","conditions":"Hypertension","enrollment":86},{"nctId":"NCT00605072","phase":"PHASE2","title":"The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2008-01","conditions":"Cognitive Impairment, Hypertension, Aging","enrollment":53},{"nctId":"NCT00005520","phase":"","title":"Genetic Epidemiology of Responses to Antihypertensives","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"1997-02","conditions":"Cardiovascular Diseases, Heart Diseases, Hypertension","enrollment":1200},{"nctId":"NCT00775814","phase":"PHASE4","title":"Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-10","conditions":"Obesity, Hypertension","enrollment":188},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00867490","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Hypertension","enrollment":186},{"nctId":"NCT00670787","phase":"PHASE3","title":"Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2008-06","conditions":"Hypertension","enrollment":207},{"nctId":"NCT00434967","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Hypertension","enrollment":2207},{"nctId":"NCT00526279","phase":"","title":"COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-06","conditions":"Hypertension","enrollment":9000},{"nctId":"NCT01012479","phase":"PHASE4","title":"Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":"Hypertension","enrollment":107},{"nctId":"NCT00621153","phase":"PHASE4","title":"Candesartan Effect in Second Stage Arterial Hypertension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Stage II Hypertension","enrollment":214},{"nctId":"NCT00282178","phase":"PHASE2","title":"Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo","status":"COMPLETED","sponsor":"Umeå University","startDate":"2005-04","conditions":"Hypertension, Obesity","enrollment":26},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00383929","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Hypertension","enrollment":1979},{"nctId":"NCT00607633","phase":"","title":"Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Essential Hypertension, Left Ventricular Hypertrophy","enrollment":686},{"nctId":"NCT00608153","phase":"","title":"Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Essential Hypertension","enrollment":1773}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ECARD® Combination Tablets LD&HD"],"phase":"marketed","status":"active","brandName":"Candesartan cilexetil / hydrochlorothiazide","genericName":"Candesartan cilexetil / hydrochlorothiazide","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Candesartan cilexetil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume. Used for Hypertension, Reduction of cardiovascular risk in hypertensive patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}